These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 20179421)

  • 1. What's the place of immunotherapy in malignant mesothelioma treatments?
    Grégoire M
    Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy and malignant mesothelioma: clinical perspectives].
    Grégoire M; Ebstein F
    Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
    Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
    Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
    Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
    Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
    Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
    Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for immunotherapy in malignant pleural mesothelioma?
    Tartarone A; Lerose R; Aieta M
    Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
    Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
    Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
    Katzman D; Sterman DH
    Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
    J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
    Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
    Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approved and emerging treatments of malignant pleural mesothelioma in elderly patients.
    Ceresoli GL; Rossi A
    Expert Rev Respir Med; 2019 Dec; 13(12):1179-1188. PubMed ID: 31596154
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
    Ceresoli GL; Bonomi M; Sauta MG
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
    Mohamed H; Eltobgy M; Abdel-Rahman O
    Anticancer Agents Med Chem; 2017; 17(9):1228-1233. PubMed ID: 28042777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's Current and What's New in Mesothelioma?
    Leal JL; Hoang W; Xue J; Dunne B; John T; Harden S
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):771-780. PubMed ID: 36155156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining chemotherapy with virotherapy: a novel treatment strategy for malignant pleural mesothelioma.
    Curiel DT; Zhu ZB
    Cancer Biol Ther; 2006 Feb; 5(2):236-7. PubMed ID: 16481733
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
    Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
    Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.